Filing Details

Accession Number:
0001933414-24-000061
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-11-12 17:25:38
Reporting Period:
2024-11-11
Accepted Time:
2024-11-12 17:25:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1933414 Mineralys Therapeutics Inc. MLYS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1672659 Malcom David Rodman 150 N. Radnor Chester Road,
Suite F200
Radnor PA 19087
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-11-11 5,017 $0.54 140,991 No 4 M Direct
Common Stock Acquisiton 2024-11-11 5,026 $1.08 146,017 No 4 M Direct
Common Stock Disposition 2024-11-11 5,026 $15.00 140,991 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2024-11-11 5,017 $0.00 5,017 $0.54
Common Stock Stock Option Disposition 2024-11-11 5,026 $0.00 5,026 $1.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,035 2031-03-11 No 4 M Direct
134,926 2032-07-11 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.05. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
  3. The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
  4. The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.